Howard L. Kaufman
Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy.
Overview
Howard Kaufman was a lead investigator and senior author of OPTiM, the phase 3 trial showing the herpes-based oncolytic virus talimogene laherparepvec improves durable response rates in advanced melanoma, leading to the first approval of an oncolytic virus in 2015. He led the JAVELIN Merkel 200 trial of avelumab and was president of the Society for Immunotherapy of Cancer.
| Title | Journal | Year |
|---|---|---|
| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma (OPTiM) | JCO | 2015 |
| Oncolytic viruses: a new class of immunotherapy drugs | Nature Reviews Drug Discovery | 2015 |
Pages like this
not linked directly; found by shared links- PersonReinhard Dummer
Shares Talimogene laherparepvec, Merkel cell carcinoma, Oncolytic viruses, Melanoma and the tag melanoma.
- PersonDirk Schadendorf
Shares Merkel cell carcinoma, Melanoma and the tags immunotherapy, melanoma.
- PersonMichael A. Postow
Shares Melanoma and the tags immunotherapy, melanoma.
- PersonCaroline Robert
Shares Melanoma and the tags immunotherapy, melanoma.
- PersonJedd D. Wolchok
Shares Melanoma and the tags immunotherapy, melanoma.
- PersonPaolo A. Ascierto
Shares Melanoma and the tags immunotherapy, melanoma.
- PersonIgor Puzanov
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
- PairingOncolytic virus + PD-1 blockade
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.